Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

About this update from Theralase Technologies Inc.

[{"type":"text","content":"Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA\n \n \n (NewsDirect)\n \n \n \n \n Theralase Technologies Inc. CEO Roger\nDuMoulin-White, joined Proactive's Stephen Gunnion to discuss the\ncompany's third-quarter 2023 operational highlights.\n \n \n The company successfully raised $1.17\nmillion, crucial for advancing its Phase II clinical study targeting\nnon-muscle invasive bladder cancer, particularly Bacillus\nCalmette-Guérin (BCG)-Unresponsive cases. The study's data shows\npromising superiority over FDA-approved drugs from major\npharmaceutical companies, making it a groundbreaking development for\nTheralase.\n \n \n DuMoulin-White detailed\nthe unique approach, utilizing a drug-device combination involving a\nlight-sensitive drug instilled into the bladder. This innovative\nmethod selectively targets cancer cells, minimizing damage to healthy\ncells, a departure from traditional pharmacological approaches.\n \n \n Currently working on its pre-Breakthrough\nTherapy Designation (BTD) with the FDA, Theralase is aiming for formal\nBTD in early 2024.\n \n \n Dumoulin-White highlighted the company's\nfocus on non-dilutive financing, potential partnerships, and\ncompleting the primary study treatment for around 100 patients by the\nend of 2024. Successful completion could lead to an FDA decision,\nideally by the end of 2026, potentially accelerated with priority\nreview.\n \n \n \n Contact Details\n \n \n \n Proactive\nInvestors\n \n \n +1 604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":2084,"tagName":"div"}]

More updates from Theralase Technologies Inc.